Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491991 | 1.00 | ITGB3 (0.54) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL17491900 | 0.88 | PPARA (0.62) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL4818304 | 0.88 | PPARA (0.62) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL16384487 | 0.87 | PPARA (0.58) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL345468 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL17492218 | 0.87 | PPARA (0.57) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL3763496 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL8239145 | 0.87 | ITGB3 (0.54) | ITGB3ITGA2BCTSSCTSKPPARA | |
| SCHEMBL17492215 | 0.87 | PPARA (0.57) | ITGB3ITGA2BPPARAPPARGPTPN1 | |
| SCHEMBL17492067 | 0.86 | PTPN1 (0.54) | ITGB3ITGA2BCTSSCTSKPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459147-B | Serine derivatives as ghrelin receptor agonists | 拉夸里亚创药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| EP-3131916-B1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9873695-B2 | Serine derivatives as ghrelin receptor agonists | RAQUALIA PHARMA INC. (JP) | 2018-01-23 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3131916-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RaQualia Pharma Inc (JP) | 2017-02-22 | — | — | EP | disclosed |
| CN-106459147-A | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | 拉夸里亚创药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| WO-2016021191-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2016-02-11 | — | — | WO | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7132533-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6967198-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK1, CHEK2, CHKA | ITGB3 4259/4885ITGA2B 4672/4885CTSS 1118/4885 |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | ITGB3 4449/4885ITGA2B 4627/4885CTSS 2216/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | ITGB3 4351/4885ITGA2B 4667/4885CTSS 1108/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | ITGB3 4318/4885ITGA2B 4715/4885CTSS 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.